These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3109063)

  • 21. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correction by factor VIII of decreased neutrophil alkaline phosphatase activity in classic haemophilia and von Willebrand's disease.
    Janković GM; Janosević S
    Haematologia (Budap); 1978-1979; 12(1-4):183-8. PubMed ID: 317061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double cryoprecipitated factor VIII concentrate from heparinised plasma and its heat treatment.
    Smit Sibinga CT; Schulting PJ; Notebomer J; Das PC; Marrink J; vd Meer J
    Blut; 1988 Mar; 56(3):111-6. PubMed ID: 3128351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on the prolonged bleeding time in von Willebrand's disease.
    Smiley RK; Tittley P; Rock G
    Thromb Res; 1989 Mar; 53(5):417-26. PubMed ID: 2499940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Von Willebrand's syndrome (author's transl)].
    Larrieu MJ; Meyer D; Ardaillou N
    Nouv Rev Fr Hematol Blood Cells; 1977; 18(2):371-82. PubMed ID: 303357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. von Willebrand factor characterization of a severe dry-heat treated factor VIII concentrate, AHF (high purity).
    Oates A; Polmear E; Herrington R; Farrugia A; Sykes S; Raines G; Aumann H; Street A
    Thromb Res; 1992 Feb; 65(3):389-99. PubMed ID: 1631803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cryoprecipitate: a safe factor VIII replacement.
    Kletzel M; Charlton R; Becton D; Berry DH
    Lancet; 1987 May; 1(8541):1093-4. PubMed ID: 2883430
    [No Abstract]   [Full Text] [Related]  

  • 28. Cryoprecipitate and Factor VIII commercial concentrates: in vitro characteristics and in vivo compartmental analysis.
    Morfini M; Longo G; Matucci M; Vannini S; Messori A; Filimberti E; Duminuco M; Avanzi G; Rossi-Ferrini P
    Ric Clin Lab; 1984; 14(4):681-91. PubMed ID: 6441235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cryoprecipitate: an outmoded treatment?
    Yang L; Stanworth S; Baglin T
    Transfus Med; 2012 Oct; 22(5):315-20. PubMed ID: 22994448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cryoprecipitate: the current state of knowledge.
    Callum JL; Karkouti K; Lin Y
    Transfus Med Rev; 2009 Jul; 23(3):177-88. PubMed ID: 19539873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress and problems in hemophilia and von Willebrand's disease.
    Abildgaard CF
    Adv Pediatr; 1984; 31():137-77. PubMed ID: 6440429
    [No Abstract]   [Full Text] [Related]  

  • 32. Preparation of Cryoprecipitate and Cryo-depleted Plasma for Proteomic Research Analysis.
    Sparrow RL; Simpson RJ; Greening DW
    Methods Mol Biol; 2023; 2628():41-49. PubMed ID: 36781778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of haemophilia patients in East Germany prior to and after reunification in 1990.
    Lenk H
    Thromb Res; 2014 Nov; 134 Suppl 1():S57-60. PubMed ID: 24745720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
    Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
    Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
    Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
    Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneity of von Willebrand's disease: study of 40 Iranian cases.
    Shoa'i I; Lavergne JM; Ardaillou N; Obert B; Ala F; Meyer D
    Br J Haematol; 1977 Sep; 37(1):67-83. PubMed ID: 303911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of DDAVP and cryoprecipitate in mild to moderate haemophilia A and von Willebrand's disease.
    Berry EW
    Prog Clin Biol Res; 1990; 324():269-78. PubMed ID: 2106689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-lymphocyte subpopulations in patients with classic hemophilia treated with cryoprecipitate and lyophilized concentrates.
    Menitove JE; Aster RH; Casper JT; Lauer SJ; Gottschall JL; Williams JE; Gill JC; Wheeler DV; Piaskowski V; Kirchner P; Montgomery RR
    N Engl J Med; 1983 Jan; 308(2):83-6. PubMed ID: 6401196
    [No Abstract]   [Full Text] [Related]  

  • 39. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evaluation of factor VIII antigen by means of a simple slide test.
    Casonato A; Fabris F; Vicariotto M; Girolami A
    Am J Clin Pathol; 1985 Jul; 84(1):107-11. PubMed ID: 3925753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.